The Incorrect Statement is B
Statement B is incorrect: Clopidogrel, prasugrel, and ticagrelor do NOT act on different platelet receptors—all three target the same P2Y12 ADP receptor. 1, 2
Analysis of Each Statement
Statement A - CORRECT
Clopidogrel and prasugrel are administered once daily (75 mg and 10 mg respectively), while ticagrelor requires twice daily dosing (90 mg bid) as maintenance therapy 1, 3. This dosing difference reflects ticagrelor's shorter half-life (6.7-9.1 hours) compared to the irreversible binding of thienopyridines 1.
Statement B - INCORRECT ❌
All three agents target the same P2Y12 ADP receptor 1, 2. The key differences are:
- Clopidogrel and prasugrel (thienopyridines): Irreversibly inhibit P2Y12 1, 2
- Ticagrelor (cyclopentyl-triazolopyrimidine): Reversibly inhibits P2Y12 through non-competitive binding at a different site than ADP 1, 4
While their binding mechanisms differ (irreversible vs. reversible), they all act on the identical receptor, making statement B false.
Statement C - CORRECT
Clopidogrel is indeed a prodrug requiring hepatic conversion via cytochrome P450 enzymes (particularly CYP2C19 and CYP3A5) to generate its active metabolite 2, 5. This metabolic requirement contributes to variable patient response and genetic polymorphism effects 5, 6.
Statement D - CORRECT
Dosing is generally not adjusted for renal function with these oral P2Y12 inhibitors 1. The table in 1 shows elimination pathways but no renal dose adjustments are standard practice. This contrasts with some parenteral antiplatelet agents where renal function matters more significantly.
Statement E - CORRECT
In patients with ACS and concurrent atrial fibrillation requiring anticoagulation, clopidogrel is preferred over prasugrel or ticagrelor 3. Prasugrel is contraindicated in patients with prior stroke/TIA 3, 5, and the increased bleeding risk with newer agents makes clopidogrel the safer choice when triple therapy (aspirin + P2Y12 inhibitor + anticoagulant) is needed 3.
Key Clinical Pearls
- Despite targeting the same receptor, prasugrel and ticagrelor provide more potent and consistent platelet inhibition than clopidogrel but with increased bleeding risk 5, 4
- The irreversible vs. reversible binding distinction affects recovery time: ticagrelor allows platelet function recovery in 3-5 days, while thienopyridines require 7 days for platelet turnover 1, 2
- Genetic polymorphisms affect clopidogrel (and to lesser extent prasugrel) but not ticagrelor, since ticagrelor doesn't require metabolic activation 5, 6, 5